Qiagen NV (WBO:QGE4) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:QGE4 Qiagen NV WBO:QGE4
72 GF Score
Price €38.60
GF Value €43.30
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Qiagen NV Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Qiagen NV  (WBO:QGE4) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Qiagen NV Cyclically Adjusted PS Ratio Related Terms


Qiagen NV Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Qiagen NV's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qiagen NV Cyclically Adjusted PS Ratio Chart

Qiagen NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.08 6.70 5.36 5.31 4.47

Qiagen NV Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.78 4.32 4.44 3.73 3.65

WBO:QGE4 vs TWST, RDNT, SHC: Cyclically Adjusted PS Ratio Comparison

For the Diagnostics & Research subindustry, Qiagen NV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qiagen NV Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Qiagen NV's Cyclically Adjusted PS Ratio falls into.


WBO:QGE4
72GF Score
Qiagen NV WBO:QGE4
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Qiagen NV Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Qiagen NV's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Qiagen NV's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.214/137.7000*137.7000
=2.214

Current CPI (Jun. 2026) = 137.7000.

Qiagen NV Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.476 100.570 2.021
201612 1.644 100.710 2.248
201703 1.372 101.440 1.862
201706 1.521 101.370 2.066
201709 1.487 102.030 2.007
201712 1.660 101.970 2.242
201803 1.342 102.470 1.803
201806 1.512 103.100 2.019
201809 1.542 103.950 2.043
201812 1.697 103.970 2.248
201903 1.467 105.370 1.917
201906 1.629 105.840 2.119
201909 1.696 106.700 2.189
201912 1.802 106.800 2.323
202003 1.624 106.850 2.093
202006 1.920 107.510 2.459
202009 1.961 107.880 2.503
202012 2.277 107.850 2.907
202103 2.263 108.870 2.862
202106 2.266 109.670 2.845
202109 2.181 110.790 2.711
202112 2.454 114.010 2.964
202203 2.716 119.460 3.131
202206 2.348 119.050 2.716
202209 2.406 126.890 2.611
202212 2.367 124.940 2.609
202303 2.190 124.720 2.418
202306 2.202 125.830 2.410
202309 2.117 127.160 2.292
202312 2.291 126.450 2.495
202403 2.020 128.580 2.163
202406 2.249 129.910 2.384
202409 2.208 131.610 2.310
202412 2.359 131.630 2.468
202503 2.196 133.330 2.268
202506 2.271 133.960 2.334
202509 2.196 135.920 2.225
202512 2.235 135.470 2.272
202603 2.014 136.840 2.027
202606 2.214 137.700 2.214

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Qiagen NV (WBO:QGE4) Overvalued in 2026?

Based on GuruFocus' analysis, Qiagen NV stock appears to be undervalued. The current stock price of €38.60 is trading 10.9% below its estimated GF Value™ of €43.30. GuruFocus considers Qiagen NV to be Modestly Undervalued.

Key valuation signals for WBO:QGE4:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €43.30 vs. price of €38.60 (10.9% below fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the WBO:QGE4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Qiagen NV Business Description

Address Hulsterweg 82, Venlo, LI, NLD, 5912 PL
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
72GF Score

Get the complete analysis for WBO:QGE4

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€38.60
Price
€43.30
GF Value